This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...

The Binney Street site currently employs about 200 people and focuses on vaccine development, ranging from discovery to manufacturing, according to GSK’s website. The site is currently dedicated ...

GSK has taken steps to keep the cost of making the vaccine low. The candidate uses GMMA technology, a platform that repurposes vesicles from bacteria to deliver antigens. One study found that a ...

In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Stay updated with the latest news on Times of India.

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a ...

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech.

FDA to decide by H1 2026 on expanding GSK's RSV vaccine to at-risk adults aged 18–49. 21 million U.S. adults under 50 have conditions putting them at risk for severe RSV. The market’s back ...

While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply.

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D for the British pharma. | After nearly 25 years with Sanofi ...